Philip O Ponce MD (He/Him)
HIV/AIDS Medicine, Transplant/Immunocompromised States, STD Medicine
Vaccines Development Medical Director Pfizer Vaccines
Join to view full profile
500 Arcola RdCollegeville, PA 19426
Phone+1 210-567-7000
Dr. Ponce is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Philip is an Infectious Diseases specialist who designs and conducts Phase 1-3 vaccine clinical trials as a vaccine development medical director for Pfizer. He is currently based in Collegeville, PA.
Clinical Expertise
- HIV/AIDS, Sexually transmitted infections, LGBT health, Primary care, Vaccines, Transplant infectious disease
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 2016 - 2018
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2024
TX State Medical License 2018 - 2024
MD State Medical License 2019 - 2019
MA State Medical License 2016 - 2018
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 1 citationsImmunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.Balachandra Giriappa, Nirmalkumar Choraria, Philip Ponce, Jelena Drozd, Xin Su
Human Vaccines & Immunotherapeutics. 2026-12-01 - 57 citationsAbatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.Jane A O'Halloran, Emily R Ko, Kevin J Anstrom, Eyal Kedar, Matthew W McCarthy
JAMA. 2023-07-25 - 88 citationsBaricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.Cameron R Wolfe, Kay M Tomashek, Thomas F Patterson, Carlos A Gomez, Vincent C Marconi
The Lancet. Respiratory Medicine. 2022-09-01
Press Mentions
The Future of MonkeypoxNovember 28th, 2022- ‘Desperate Need’: San Antonio Doctors Use COVID-Positive Donor Organs for Kidney, Liver TransplantsSeptember 2nd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: